Sernova (SVA) Competitors C$0.16 +0.01 (+3.33%) As of 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock SVA vs. FRX, BCT, IPA, TH, SCYB, COM, NVH, IGX, ONC, and PDPShould you be buying Sernova stock or one of its competitors? The main competitors of Sernova include Fennec Pharmaceuticals (FRX), BriaCell Therapeutics (BCT), ImmunoPrecise Antibodies (IPA), Theratechnologies (TH), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), IntelGenx Technologies (IGX), Oncolytics Biotech (ONC), and Pediapharm (PDP). These companies are all part of the "biotechnology" industry. Sernova vs. Its Competitors Fennec Pharmaceuticals BriaCell Therapeutics ImmunoPrecise Antibodies Theratechnologies Scythian Biosciences 138267 (COM.TO) Novoheart IntelGenx Technologies Oncolytics Biotech Pediapharm Sernova (TSE:SVA) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings. Which has more volatility and risk, SVA or FRX? Sernova has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500. Comparatively, Fennec Pharmaceuticals has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500. Do insiders & institutionals have more ownership in SVA or FRX? 0.1% of Sernova shares are owned by institutional investors. Comparatively, 52.8% of Fennec Pharmaceuticals shares are owned by institutional investors. 12.1% of Sernova shares are owned by insiders. Comparatively, 16.2% of Fennec Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts rate SVA or FRX? Sernova presently has a consensus price target of C$2.00, indicating a potential upside of 1,190.32%. Given Sernova's higher possible upside, research analysts plainly believe Sernova is more favorable than Fennec Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sernova 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Fennec Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Does the media prefer SVA or FRX? In the previous week, Fennec Pharmaceuticals had 4 more articles in the media than Sernova. MarketBeat recorded 5 mentions for Fennec Pharmaceuticals and 1 mentions for Sernova. Sernova's average media sentiment score of 0.75 beat Fennec Pharmaceuticals' score of 0.10 indicating that Sernova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sernova 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fennec Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation and earnings, SVA or FRX? Fennec Pharmaceuticals has higher revenue and earnings than Sernova. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Sernova, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSernovaN/AN/A-C$35.70M-C$0.10-1.50Fennec PharmaceuticalsC$34.86M6.73-C$800.44K-C$0.06-205.99 Is SVA or FRX more profitable? Sernova has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -2.30%. Sernova's return on equity of 473.85% beat Fennec Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets SernovaN/A 473.85% -119.26% Fennec Pharmaceuticals -2.30%29.94%8.88% SummaryFennec Pharmaceuticals beats Sernova on 8 of the 15 factors compared between the two stocks. Get Sernova News Delivered to You Automatically Sign up to receive the latest news and ratings for SVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SVA vs. The Competition Export to ExcelMetricSernovaBiotechnology IndustryMedical SectorTSE ExchangeMarket CapC$52.16MC$128.01MC$5.53BC$6.19BDividend Yield7.86%3.74%5.24%6.72%P/E Ratio-1.503.4227.5050.85Price / SalesN/A4,204.64421.021,194.53Price / Cash6.1513.1936.8983.29Price / Book-3.6343.018.044.70Net Income-C$35.70M-C$92.79MC$3.18BC$301.20M7 Day Performance-6.06%2.66%2.82%2.31%1 Month Performance-8.82%2.53%3.70%4.86%1 Year Performance-53.73%178.37%35.41%26.45% Sernova Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SVASernova2.7408 of 5 starsC$0.16+3.3%C$2.00+1,190.3%-55.2%C$52.16MN/A-1.501,959Gap DownFRXFennec PharmaceuticalsN/AC$11.44+6.2%N/A+45.7%C$220.62MC$34.86M-193.7910News CoverageInsider TradeGap UpBCTBriaCell TherapeuticsN/AC$10.60-3.8%C$15.00+41.5%+0.0%C$168.68MN/A-28.195IPAImmunoPrecise AntibodiesN/AC$6.50+0.8%N/A+0.0%C$162.08MC$19.47M-7.3080Gap DownTHTheratechnologiesN/AC$3.37-0.6%N/A+127.4%C$107.52MC$52.22M-38.15103News CoverageAnalyst DowngradeSCYBScythian BiosciencesN/AC$3.49-5.9%N/A+0.0%C$102.38MN/A0.00N/AHigh Trading VolumeCOM138267 (COM.TO)N/AN/AN/AN/AC$102.19MN/A0.00N/ANVHNovoheartN/AC$0.53+1.9%N/A+0.0%C$99.98MC$423.50K-13.95N/AIGXIntelGenx TechnologiesN/AC$0.58+1.8%N/A+0.0%C$87.32MC$1.75M-7.442,050Gap UpONCOncolytics Biotech1.1081 of 5 starsC$0.88+2.3%C$3.50+297.7%-12.1%C$67.83MN/A-2.4529PDPPediapharmN/AC$0.30+1.7%N/A+0.0%C$66.36MC$11.16M-4.11N/A Related Companies and Tools Related Companies Fennec Pharmaceuticals Alternatives BriaCell Therapeutics Alternatives ImmunoPrecise Antibodies Alternatives Theratechnologies Alternatives Scythian Biosciences Alternatives 138267 (COM.TO) Alternatives Novoheart Alternatives IntelGenx Technologies Alternatives Oncolytics Biotech Alternatives Pediapharm Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (TSE:SVA) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredRevealed: NEW A.I. revolution (nobody is talking about)Nvidia's CEO says this is: "The next wave of A.I." We're at the cusp of a new "A.I. Upgrade" that is set to...Behind the Markets | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sernova Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sernova With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
